Study of mogamulizumab plus chemotherapy for T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a drug called mogamulizumab combined with standard chemotherapy (DA-EPOCH or CHOEP) for people with aggressive T-cell lymphoma. It aims to see if the combination is safe and works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a confirmed diagnosis of T-cell non-Hodgkin lymphoma (a type of cancer that affects immune cells).
- You should be able to take care of yourself (ECOG score 0-2) or benefit from treatment even if you are more ill.
- You can have had up to one cycle of standard chemotherapy before joining, if needed to control the disease.
- For certain types of T-cell lymphoma, you must have at least one tumor that is 1.5 cm or larger.
- You must have adequate organ and bone marrow function, unless problems are caused by the lymphoma itself.
- Women must not be pregnant or breastfeeding, and both men and women must use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
This trial tests whether a drug called mogamulizumab can prevent adult T-cell leukemia/lymphoma in people who carry the HTLV-1 virus and have a high viral load. It is for patients who have not yet developed the blood cancer.
This trial tests whether doing your own stem cell transplant, followed by polatuzumab, can improve outcomes in people with specific B-cell non-Hodgkin or Hodgkin lymphomas that did not fully respond or has come back. It aims to add a targeted medicine after transplant to help control the lymphoma.
This early-phase study tests a combination of “natural killer” immune cells and a medicine called mogamulizumab to treat certain skin lymphomas that have come back or did not respond. It may help your immune system better find and attack cancer cells.
This trial studies mogamulizumab (an antibody medicine) plus total skin electron beam therapy (whole-skin radiation) to treat cutaneous T-cell lymphoma. It may help by improving skin symptoms and controlling the lymphoma after prior treatments.
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
Hear when a new T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.